

# CONTENTS

Vol.43 No.2 March 2012

Japanese Journal of Clinical Pharmacology  
and Therapeutics

## **Special Articles**

Current Status and Defect on the Development of DDS Preparations Kanji TAKADA 51

## **Original**

Investigation of Bioequivalence between MSG203 and Paxil® (Paroxetine Hydrochloride Hydrate) after Single Oral Administration in Japanese Healthy Male Subjects : Detailed Study in Different CYP2D6 Phenotypes Naoki UCHIDA, et al. 57

## **Forum**

Psychological Analysis of Parents Whose Children Participated in Pediatric Clinical Trials Shigehiro UEYAMA, et al. 65

## **Report**

Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 1 Harumasa NAKAMURA 73  
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 1 Masaya KOSHIZAKA 77

## **Proceedings of the 32nd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics**

Contents 81  
Symposium 2 "Development of Clinical Pharmacological Study Using Human Tissues" 83  
Symposium 6 "The Advance of Chronopharmacology" 95  
Symposium 15 "Toward Effective Therapeutic Team to Promote Rational Drug Therapy" 105  
Symposium 18 "Current Drug Treatment Strategies for Alzheimer's Disease and Parkinson's Disease" 119

**Drug Information** 33E

**Information for Authors** 35E

**Announcements** 37E

**Proceedings of the 32nd Annual Meeting of the Japanese Society of Clinical Pharmacology  
and Therapeutics**

December 1-3, 2011 (Hamamatsu)

President: Hiroshi WATANABE (Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine)

**Symposium 2 “Development of Clinical Pharmacological Study Using Human Tissues”**

Summary	Toshio KUMAI, et al.	83
S2-1 The Human Tissue Bank for Medical Research in St. Marianna University School of Medicine Hospital	Sachiko TAKENOSHITA-NAKAYA	85
S2-2 Possible Role of HAB Research Organization in Human Biomaterial Procurement in Japan	Satoshi SUZUKI, et al.	87
S2-3 Providing Human Tissues and Cells for Biomedical Research	Takuo KOSAKA	89
S2-4 Development of Exon Skipping Therapy for Duchenne Muscular Dystrophy Using Patient-Derived Cells	Takashi SAITO, et al.	91
S2-5 Expression Profile of Cytochrome P450s in the Small Intestine of Japanese	Yuko TAKEBA, et al.	93

**Symposium 6 “The Advance of Chronopharmacology”**

Summary	Toshiyuki SASAGURI, et al.	95
S6-1 Biological Rhythms and Drug Discovery	Shigenobu SHIBATA	97
S6-2 Chronopharmacokinetics Based on Molecular Clock	Shigehiro OHDO, et al.	99
S6-3 Biological Rhythm and Drug Adverse Effect	Akio FUJIMURA	101
S6-4 Chronotherapy with Antihypertensive Drugs	Keiko UEZONO	103

**Symposium 15 “Toward Effective Therapeutic Team to Promote Rational Drug Therapy”**

Summary	Shigeyuki NAKANO, et al.	105
S15-1 Introduction : Trend in Interdisciplinary Approach in Healthcare Policy	Junichi KAWAKAMI	107
S15-2 Multidisciplinary Team Approaches and Roles of Pharmacists in Cancer Therapy	Tomohiro TERADA, et al.	109
S15-3 Interdisciplinary Approach to Anti-Infectious Pharmacotherapy in the Intensive Care Unit through the Therapeutic Drug Monitoring	Takafumi NAITO, et al.	111
S15-4 In Case of Clinical Trials Team	Toshiko ISHIBASHI	113
S15-5 Promoting Cooperation between Healthcare Professionals and Patients	Kyoko KITAZAWA	115
S15-6 Education for Therapeutic Team Members to Promote Rational Drug Therapy	Shigeyuki NAKANO	117

**Symposium 18 “Current Drug Treatment Strategies for Alzheimer’s Disease and Parkinson’s Disease”**

Summary	Masahiro NAGAI, et al.	119
S18-1 Neurological Disorders : PMDA’s Role in New Product Development	Takashi MORITOYO	121
S18-2 Perspectives on the Future Therapeutics of Alzheimer Disease	Hiroaki MIYAJIMA	123
S18-3 Strategies of Drug Development for Neurodegenerative Disorders --Development of Antiparkinson Drugs	Akihisa MORI	125
S18-4 Current Status and Future Prospects of Antiparkinsonian Agents	Masahiro NAGAI	127